Growth hormone secretagogues explained

The pituitary already has the growth hormone

A growth hormone secretagogue is a compound that tells the pituitary gland to release the growth hormone (GH) it already has stored in its somatotroph cells. That framing matters because it separates secretagogues from exogenous recombinant GH (products like Genotropin or Humatrope), which supply GH directly from outside the body. Secretagogues instead trigger the body's own pulsatile release — a rhythm that has clinical implications, because pulsatile GH is what physiologically regulates IGF-1 elevation, tissue signalling, and downstream metabolic effects. When people talk about 'GH peptides' in the research-peptide space, they are almost always talking about secretagogues, not recombinant GH.

Two receptor systems, one target cell

The somatotrophs of the anterior pituitary carry two receptor systems that both drive GH release: the growth-hormone-releasing hormone receptor (GHRH-R) and the growth-hormone secretagogue receptor (GHS-R, also known as the ghrelin receptor). GHRH-R is the classical physiological pathway — hypothalamic GHRH neurones fire in coordinated bursts that make the somatotrophs release GH in a pulse. GHS-R evolved to sense ghrelin, the 'hunger hormone' produced by the stomach, and its activation also releases GH but through a different intracellular signalling cascade. The two systems are complementary rather than redundant. When both receptors are activated simultaneously in a coordinated pulse, the somatotroph releases substantially more GH than either signal alone would evoke — the pharmacological basis for stacking a GHRH analogue with a ghrelin-receptor agonist. This synergy is why the CJC-1295 / Ipamorelin blend and similar combinations dominate the practical secretagogue space.

GHRH-R + GHS-R activated together produces a larger GH pulse than either signal alone — the pharmacological basis for stacking these two peptide families.

The GHRH-analogue family

Native GHRH is a 44-amino-acid peptide with a plasma half-life of minutes, degraded rapidly by dipeptidyl peptidase-4 (DPP-4). The clinical GHRH analogues in the research-peptide catalog are stabilised variants that resist DPP-4 degradation. Sermorelin is a 29-amino-acid truncation retaining the biologically active N-terminus but sharing native GHRH's short half-life. CJC-1295 No DAC is a 30-amino-acid variant with substitutions that resist DPP-4 more effectively — a short, sharp GH pulse rather than the continuous elevation. CJC-1295 DAC adds a drug affinity complex (DAC) that binds serum albumin and dramatically extends the plasma half-life to roughly a week — producing a continuous GHRH elevation rather than a pulsatile signal. Tesamorelin is a stabilised GHRH analogue with documented visceral-fat-reduction pharmacology in the peer-reviewed literature, supported by the Falutz 2007 NEJM pivotal trial. Each variant produces a different pharmacokinetic profile, and choosing between them is a choice about pulsatile vs continuous stimulation.

The ghrelin-mimetic family

Ghrelin is the endogenous ligand of GHS-R. Ghrelin mimetics are peptides designed to activate the same receptor. The first generation of these was the GHRP series — GHRP-2, GHRP-6, hexarelin — which produced strong GH stimulation but also elevated cortisol, prolactin, and ACTH as off-target effects (Bowers 1984 and later characterisations). Those parallel HPA-axis elevations were consistent with GHS-R crosstalk in the hypothalamus and undermined the metabolic benefit of the GH pulse itself. Ipamorelin was engineered specifically to activate GHS-R without the cortisol / prolactin / ACTH effects — the mechanism-defining property that makes ipamorelin the ghrelin agonist of choice in modern GH-secretagogue stacks. When paired with a GHRH analogue (CJC-1295 No DAC or Tesamorelin), the result is a GH-axis modulation with minimal collateral endocrine noise.

Why timing and fasting matter as much as dose

The physiological GH pulse in humans occurs predominantly during early sleep — this is well-characterised endocrinology, established in the classical studies of nocturnal GH release. A secretagogue given at bedtime reinforces the natural pulse and produces the largest response. A secretagogue given during the day, particularly with recent food, produces a much smaller effect. The reason is insulin: postprandial insulin suppresses somatotroph responsiveness to both GHRH and ghrelin. Carbohydrate ingestion within 30–60 minutes before injection substantively blunts the GH pulse. Practical GH-secretagogue protocols therefore emphasise fasted pre-sleep injection — not because it is convenient but because timing and fasting substantially change the pharmacological output. This is one of the most common errors in grey-market use: injecting at random times or with recent food dramatically reduces the effect, and the resulting 'nothing happened' outcome is often attributed to product failure when it actually reflects protocol error.

Cycling and receptor desensitisation

Sustained continuous activation of any GPCR tends to produce receptor desensitisation over time — a general phenomenon in GPCR pharmacology documented across many receptor families. For GH secretagogues this means the somatotrophs become progressively less responsive to repeated GHRH or ghrelin signal if the stimulation is not interrupted. The general cycling framework in the research-peptide space (3 months on, 1 month off) is derived from this concern, though clinically-validated cycle durations for grey-market use do not exist. Sermorelin and Tesamorelin, both of which have historical clinical use as continuous therapy in specific indications, follow different rules — Sermorelin has been used long-term in paediatric GHD contexts, and Tesamorelin's approved-drug-population regimen is continuous daily dosing. The cycling framework applies most clearly to the research-peptide grey-market context and is a general precautionary convention rather than a clinical requirement.

Common questions

References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone· Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · 2006
• Ipamorelin, the first selective growth hormone secretagogue· Raun K, Hansen BS, Johansen NL, et al. · 1998
• A phase 3, randomised, placebo-controlled trial of tesamorelin (a growth hormone–releasing factor analogue) in HIV-infected patients with excess abdominal fat· Falutz J, Allas S, Blot K, et al. · 2007
• Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation — a randomised clinical trial· Stanley TL, Feldpausch MN, Oh J, et al. · 2014

Links open external, peer-reviewed sources. Healthy Mango does not host trial data.